Lebrikizumab reduced interference of itch on sleep at 52 weeks in patients with moderate-to- severe atopic dermatitis: pooled analysis of two phase 3 randomized controlled trials

被引：0
|
作者：
Yosipovitch, Gil [1 ]
Lio, Peter A. [2 ]
Rosmarin, David [3 ]
Legat, Franz J. [4 ]
Carrascosa, Jose-Manuel [5 ]
Meskimen, Eric [6 ]
Casillas, Marta [6 ]
Pierce, Evangeline [6 ]
Xu, Chenjia [6 ]
Zhong, Jinglin [7 ]
Staender, Sonja [8 ]
机构：
[1] Univ Miami, Miller Sch Med, Coral Gables, FL USA
[2] Northwestern Univ, Feinberg Sch Med, Chicago, IL USA
[3] Tufts Univ, Sch Med, Boston, MA USA
[4] Med Univ Graz, Graz, Austria
[5] Hosp Badalona Germans Trias & Pujol, Barcelona, Spain
[6] Eli Lilly & Co, Indianapolis, IN USA
[7] IQVIA, Rockville, MD USA
[8] Univ Hosp Munster, Munster, Germany
来源：
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY | 2023年 / 89卷 / 03期
关键词：
D O I：
暂无
中图分类号：
R75 [皮肤病学与性病学];
学科分类号：
100206 ;
摘要：
41916
引用
收藏
页码：AB61 / AB61
页数：1
相关论文
共 50 条
  • [21] Efficacy and Safety of Lebrikizumab in moderate to severe atopic Dermatitis: Results of two randomized, double-blind, placebo-controlled phase III Studies (ADvocate1 and ADvocate2) at 52 Weeks
    Blauvelt, A.
    Thyssen, J. P.
    Guttman-Yassky, E.
    Bieber, T.
    Serra-Baldrich, E.
    Simspon, E.
    Rosmarin, D.
    Diemert, S.
    Elmaraghy, H.
    Silverberg, J.
    ALLERGOLOGIE, 2023, 46 (08) : 530 - 530
  • [22] Effect of upadacitinib on atopic hand eczema in patients with moderate-to-severe atopic dermatitis: Results from two randomized phase 3 trials
    Simpson, E. L.
    Rahawi, K.
    Hu, X.
    Chu, A. D.
    Nduaka, C.
    Jazayeri, S.
    Lio, P.
    Lynde, C.
    Schuttelaar, M. L. A.
    JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY, 2023, : 1863 - 1870
  • [23] ABROCITINIB MONOTHERAPY PROVIDES RAPID AND SUSTAINED ITCH IMPROVEMENT AT VARIOUS THRESHOLDS OF RESPONSE IN PATIENTS WITH MODERATE-TO-SEVERE ATOPIC DERMATITIS: A POOLED ANALYSIS OF THREE RANDOMIZED TRIALS
    Kwatra, Shawn G.
    Guttman-Yassky, Emma
    Biswas, Pinaki
    Myers, Daniela E.
    Guler, Erman
    Gooderham, Melinda J.
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 21 - 21
  • [24] Efficacy and Safety of Lebrikizumab in Combination with Topical Corticosteroids in Patients with Moderate-to-Severe Atopic Dermatitis: A Phase 3, Randomized, Placebo-Controlled Trial (ADhere)
    Simpson, Eric L.
    Gooderham, Melinda
    Wollenberg, Andreas
    Weidinger, Stephan
    Armstrong, April
    Soung, Jennifer
    Ferrucci, Silvia
    Lima, Renata Gontijo
    Xu, Wen
    Witte, Michael M.
    Blauvelt, Andrew
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 61
  • [25] Lebrikizumab monotherapy impacts on quality of life scores through improved itch and sleep interference in two Phase 3 trials
    Soung, Jennifer
    Stander, Sonja
    Gutermuth, Jan
    Pau-Charles, Ignasi
    Dawson, Zach
    Yang, Fan Emily
    Sun, Luna
    Pierce, Evangeline
    Elmaraghy, Hany
    Stein-Gold, Linda
    JOURNAL OF DERMATOLOGICAL TREATMENT, 2024, 35 (01)
  • [26] EFFICACY OF ABROCITINIB AND DUPILUMAB IN PATIENTS WITH ITCH-DOMINANT ATOPIC DERMATITIS: A POOLED ANALYSIS OF 2 RANDOMIZED TRIALS
    Silverberg, Jonathan I.
    Thyssen, Jacob P.
    Lazariciu, Irina
    Valdez, Hernan
    Myers, Daniela E.
    Gueler, Erman
    Chovatiya, Raj
    ACTA DERMATO-VENEREOLOGICA, 2022, 102 : 31 - 32
  • [27] Efficacy and Safety of Lebrikizumab in Moderate-to-Severe Atopic Dermatitis: 52-Week Results of Two Randomized, Double-Blinded, Placebo-Controlled Phase 3 Trials (ADvocate1 and ADvocate2)
    Marquardt, Tzvetelina
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Guttman-Yassky, Emma
    Bieber, Thomas
    Serra-Baldrich, Esther
    Simpson, Eric
    Rosmarin, David
    Elmaraghy, Hany
    Meskimen, Eric
    Natalie, Chitra R.
    Liu, Zhuqing
    Xu, Chenjia
    Pierce, Evangeline
    Morgan-Cox, MaryAnn
    Silverberg, Jonathan
    JOURNAL DER DEUTSCHEN DERMATOLOGISCHEN GESELLSCHAFT, 2023, 21 : 61 - 62
  • [28] Injection site reactions from an integrated analysis of phase 2 and phase 3 clinical trials of lebrikizumab treatment in moderate-to-severe atopic dermatitis
    Gooderham, Melinda
    Shi, Vivian Y.
    Wollenberg, Andreas
    Thyssen, Jacob P.
    Torres, Tiago
    Gil, Esther Garcia
    Bardolet, Laia
    Natalie, Chitra R.
    Atwater, Amber R.
    Zhao, Fangyi
    Blauvelt, Andrew
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [29] Efficacy and safety of lebrikizumab in moderate-to-severe atopic dermatitis: 52-week results of two randomized, double-blinded, placebo-controlled phase 3 trials (ADvocate1 and ADvocate2)
    Blauvelt, Andrew
    Thyssen, Jacob P.
    Guttman-Yassky, Emma
    Bieber, Thomas
    Carrascosa, Jose Manuel
    Simpson, Eric
    Rosmarin, David
    Elmaraghy, Hany
    Meskimen, Eric
    Natalie, Chitra R.
    Liu, Zhuqing
    Xu, Chenjia
    Pierce, Evangeline
    Morgan-Cox, MaryAnn
    Silverberg, Jonathan, I
    BRITISH JOURNAL OF DERMATOLOGY, 2023, 188
  • [30] Itch-free state in patients with atopic dermatitis treated with ruxolitinib cream: A pooled analysis from two randomized phase 3 studies
    Blauvelt, Andrew
    Szepietowski, Jacek C.
    Papp, Kim
    Simpson, Eric L.
    Silverberg, Jonathan L.
    Kim, Brian S.
    Kwatra, Shawn G.
    Kuligowski, Micahel E.
    Venturanza, May E.
    Wei, Shaoceng
    Kircik, Leon
    JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2023, 88 (03) : 651 - 653
12345